» Articles » PMID: 30774776

Contribution of Promoter Region Gene Polymorphism to Early-onset Prostate Cancer Risk in Mexican Males

Overview
Journal Oncotarget
Specialty Oncology
Date 2019 Feb 19
PMID 30774776
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Sexually transmitted infections and its contribution to prostate cancer (PC) development have been relevant in different populations. gene polymorphism (rs10993994) has exhibited an association both with PC as well as the susceptibility to sexually transmitted infections. Hitherto, these conditions have been not studied in Mexico yet, neither if sexually transmitted infections could modify the MSMB and PC association. Herein, socio-demographic features, sexually transmitted infections records, the reproductive backgrounds, and the genetic characterisation were analysed in 322 incident PC cases and 628 population healthy controls from Mexico City. Whole PC, early-onset PC (PC at < 60 years old), late-onset PC (≥ 60 years old), and PC aggressiveness were used to evaluate the genetic variants contribution to PC risk using unconditional logistic regression models. Overall, none associations between the allelic variants of rs10993994 polymorphisms with whole and PC aggressiveness were found. Howbeit, the TT genotype carriers presented the highest susceptibility to develop early-onset PC (OR = 2.66; 95% CI = 1.41, 5.04; = 0.03) than CC+CT carriers, both with codominant and recessive models. Although none association between whole PC and gene polymorphism was found, our results were reinforced by prior studies in European descendent populations, suggesting a contribution between rs10993994 and early-onset PC development.

Citing Articles

Role of genetic variations and protein expression of β-Microsemino protein in intrauterine insemination outcome of unexplained infertile men: A case-control study.

Bagherian E, Jokari S, Boroujeni P, Haratian K, Sabbaghian M, Meybodi A Int J Reprod Biomed. 2024; 22(6):481-494.

PMID: 39205920 PMC: 11347762. DOI: 10.18502/ijrm.v22i6.16799.


LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer.

Vezelis A, Simiene J, Dabkeviciene D, Kincius M, Ulys A, Suziedelis K J Oncol. 2021; 2021:8820366.

PMID: 33488712 PMC: 7803409. DOI: 10.1155/2021/8820366.

References
1.
Wacholder S, Rothman N, Caporaso N . Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst. 2000; 92(14):1151-8. DOI: 10.1093/jnci/92.14.1151. View

2.
Gronberg H . Prostate cancer epidemiology. Lancet. 2003; 361(9360):859-64. DOI: 10.1016/S0140-6736(03)12713-4. View

3.
Humphrey P . Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004; 17(3):292-306. DOI: 10.1038/modpathol.3800054. View

4.
Bostwick D, Burke H, Djakiew D, Euling S, Ho S, Landolph J . Human prostate cancer risk factors. Cancer. 2004; 101(10 Suppl):2371-490. DOI: 10.1002/cncr.20408. View

5.
Ewis A, Lee J, Naroda T, Sano T, Kagawa S, Iwamoto T . Prostate cancer incidence varies among males from different Y-chromosome lineages. Prostate Cancer Prostatic Dis. 2006; 9(3):303-9. DOI: 10.1038/sj.pcan.4500876. View